CARE™ Update:

Biosimilars & Access to Innovation

Updates, Considerations and Moving Forward

Access to Innovation


12 Nov 2019

CARE™ Faculty most recently met with representatives from government, HTAs, public and private payers, and patient groups on September 19th, 2019 during the annual CARE™ Summit. The purpose of this meeting was to get updates from relevant stakeholders on actions relating to biosimilars and access to innovation to see how positions are changing.

This report provides a recap of where we left off after the 2019 CARE™ Congress on Access to Innovation in April as discussed during the CARE™ Summit, as well as a summary of other key discussion/updates and outstanding questions with biosimilars and access to innovation. This content is drawn from the discussion between stakeholder representatives and CARE™ Faculty specialists during the meeting.